ArticleBlood advances2023

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Diego Villa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.